Aclarion, Inc. (ACON): Nasdaq/NYSE listing notice — Aclarion receives Nasdaq notice of non-compliance with minimum bid price rule

Aclarion, Inc.

Received Nasdaq notice on April 8, 2024 for failing minimum bid price of $1.00 per share over 30 consecutive business days.
Has 180 calendar days (until October 7, 2024) to regain compliance by having bid price close at or above $1.00 for 10 consecutive days.
May be eligible for an additional 180-day period if it meets other listing requirements and intends to effect a reverse stock split if needed.
Company intends to monitor bid price and consider options to regain compliance; delisting is not immediate.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 1.0

Aclarion, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 8, 2024, Aclarion, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per

View on SEC.gov

Browse all listing & compliance notices →

Aclarion, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-002343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.